Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002

Abstract

Few studies have addressed longer‐term survival for breast cancer in European women. We have made predictions of 10‐year survival for European women diagnosed with breast cancer in 2000–2002. Data for 114,312 adult women (15–99 years) diagnosed with a first primary malignant cancer of the breast during 2000–2002 were collected in the EUROCARE‐4 study from 24 population‐based cancer registries in 14 European countries. We estimated relative survival at 1, 5, and 10 years after diagnosis for women who were alive at some point during 2000–2002, using the period approach. We also estimated 10‐year survival conditional on survival to 1 and 5 years after diagnosis. Ten‐year survival exceeded 70% in most regions, but was only 54% in Eastern Europe, with the highest value in Northern Europe (about 75%). Ten‐year survival conditional on survival for 1 year was 2–6% higher than 10‐year survival in all European regions, and geographic differences were smaller. Ten‐year survival for women who survived at least 5 years was 88% overall, with the lowest figure in Eastern Europe (79%) and the highest in the UK (91%). Women aged 50–69 years had higher overall survival than older and younger women (79%). Six cancer registries had adequate information on stage at diagnosis; in these jurisdictions, 10‐year survival was 89% for local, 62% for regional and 10% for metastatic disease. Data on stage are not collected routinely or consistently, yet these data are essential for meaningful comparison of population‐based survival, which provides vital information for improving breast cancer control.

Sobrevida de dez anos e fatores prognósticos para o câncer de mama na região Sudeste do Brasil

“…In the study carried out by Allemani et al 17 , which was based on data records of the population, the relative ten-year survival among European women with breast cancer diagnosed between 2000 and 2002 showed values above 70% in most regions of the European continent. This percentage corroborates the results obtained by Soerjomataram et al 9 in a systematic review, in which they concluded that most Western developed countries had tenyear survival rates of around 70.0%.…”

Disease-free survival in patients with non-metastatic breast cancer

“…31 Allemani et al noted relative survival estimates of 89% for patients with tumors confined to the breast and 62% for tumors with lymph node involvement. 32 Kim et al showed DFS of 113 months for patients with breast cancer with no lymph node involvement and 84 months for those who presented lymph node metastases. 33 Adjuvant hormone therapy with tamoxifen was responsible for a reduction in the risk of recurrence of 41% and in the risk of death from breast cancer of 34% in women in a study by the Early Breast Cancer Trialists' Collaborative Group -EBCTCG.…”

Zróżnicowanie wyleczalności chorych na wybrane nowotwory złośliwe w Polsce na tle krajów europejskich w latach 2005–2009 na podstawie badania CONCORD 2

“…Przyczyny utrzymującego się zróżnicowania przeżyć w krajach europejskich budzą wiele kontrowersji, głównie w środowiskach lekarskich i decydenckich, toteż podjęto dalsze szczególowe badania oparte na danych klinicznych typu High Resolution, które dostarczają kolejnych dowodów, że proporcja pacjentów we wczesnym stopniu zaawansowania choroby nowotworowej oraz dostępność leczenia uznanego za optymalne ma największe znaczenie w kształtowaniu wskaźników 5-letnich przeżyć w populacji [19][20][21]. Wiedza ta ma fundamentalne znaczenie dla określania potrzeb i budowania strategii walki z rakiem oraz w ocenie jej efektywności zdrowotnej.…”

“…Wiedza ta ma fundamentalne znaczenie dla określania potrzeb i budowania strategii walki z rakiem oraz w ocenie jej efektywności zdrowotnej. [19,20,[22][23][24][25].…”